We first performed a syngeneic mouse model by subcutaneously injecting LLC cells into immunocompetent C57BL/6 mice and measuring the tumor growth and immune cell profiling with or without intravenous (i.v.)injection of CHI3L1 nAbs (5 μg/g) once every three days, starting on day 3 until day 12 (Figure 5A). The gene discussed is CHI3L1; the disease is neoplasm.